Phase 2/3 Study of ALK-001 in Geographic Atrophy

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic

In brief

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

Key facts

Study ID
NCT03845582
Run by
Alkeus Pharmaceuticals, Inc.
People needed
200
Starts
2019-05-07
Expected to finish
2024-06-30
Last updated by the study team
2025-11-03

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.